Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

4198 - Open label non-randomized multi-cohort pilot study of genetically engineered NY-ESO-1 specific NY-ESO-1c259 SPEAR T-cellsTM in HLA-A*02+ patients with synovial sarcoma (NCT01343043)


09 Oct 2016


Poster display


Crystal Mackall


Annals of Oncology (2016) 27 (6): 359-378. 10.1093/annonc/mdw378


C. Mackall1, S. D'Angelo2, S. Grupp3, J. Glod4, M. Druta5, W. Chow6, K. Chagin7, M. Mehler8, G. Kari8, T. Trivedi8, T. Holdich9, L. Pandite8, R. Amado8

Author affiliations

  • 1 Stanford Cancer Institute, Stanford University Medical Center, 94305 - Stanford/US
  • 2 Medicine, Memorial Sloan Kettering Cancer Center, New York/US
  • 3 Pediatrics, Children's Hospital of Philadelphia, Philadelphia/US
  • 4 Center For Cancer Research, National Cancer Institute, Washington/US
  • 5 Oncology, Moffitt Cancer Center, Tampa/US
  • 6 Medical Oncology, City of Hope, Duarte/US
  • 7 Global Clinical Development, Adaptimmune, Philadelphia/US
  • 8 Global Clinical Development, Adaptimmune LLC, Philadelphia/US
  • 9 Global Clinical Development, Adaptimmune LTD, Oxford/GB


Abstract 4198


NY-ESO-1, a member of the cancer-testis family of tumor antigens, is expressed in ∼ 70% of Synovial Sarcoma (SS) cases. NY-ESO-1c259 SPEAR T-cellsTM recognizing the NY-ESO-1 derived SLLMWITQC peptide complexed with HLA-A*02 have been developed for study in SS.


The primary endpoint of overall response rate [ORR (CR + PR)] will be evaluated in high NY-ESO expressers [2 + , 3+ NY-ESO in ≥50% of tumor cells by IHC (Cohorts 1, 3, and 4)] and low expressers [1+ in >1%, 2 + , 3+ in


Enrollment in cohort 1 is complete (12 pts), ongoing in cohorts 2 and 3 (2 in each). ORR in cohort 1 is 50% (1 CR; 5 PR). Two pts receiving non target doses (


The NY-ESO-1c259 SPEAR T-cellsTM have promising efficacy and acceptable safety profile in pts with SS who highly express NY-ESO. Efficacy and safety data will be further evaluated and presented from subjects enrolled in all cohorts.

Clinical trial identification


Legal entity responsible for the study

Adaptimmune LLC


Adaptimmune LLC


K. Chagin, M. Mehler, G. Kari, T. Trivedi, T. Holdich, R. Amado: Author is an employee of Adaptimmune. L. Pandite: I am an employee of Adaptimmune. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings